Back to top
more

IDEXX Laboratories (IDXX)

(Delayed Data from NSDQ)

$472.35 USD

472.35
432,975

+3.17 (0.68%)

Updated Sep 6, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 249)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Urmimala Biswas headshot

3 Top Medical Instruments Stocks to Beat COVID-19 Resurgence Crisis

by Urmimala Biswas

Despite the severe challenges posed by the COVID-19 pandemic, higher demand for telemedicine, digital influence and AI is likely to lend support to the Zacks Medical - Instruments industry. NTUS, IDXX and HOLX are well positioned to gain.

AmerisourceBergen (ABC) Hits New 52-Week High: What's Driving It?

by Zacks Equity Research

AmerisourceBergen (ABC) is optimistic about maintaining a robust segmental performance amid the pandemic-led business disruptions.

Here's Why You Should Retain PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) continues to gain traction for solid product portfolio and improving margins. However, forex is a woe

Debanjana Dey headshot

5 MedTech Growth Stocks Gaining Ground in 2021 Amid Pandemic

by Debanjana Dey

Here are a few MedTech stocks, ABT, HOLX, HRC, IDXX, LMAT, which have held their ground amid the pandemic and can turn out to be wise investment choices for 2021.

Zacks.com featured highlights include: Toll Brothers, Goldman Sachs, Owens Corning, CBRE Group and IDEXX Laboratories

by Zacks Equity Research

Zacks.com featured highlights include: Toll Brothers, Goldman Sachs, Owens Corning, CBRE Group and IDEXX Laboratories

Sanghamitra Saha headshot

5 Best Stocks Likely to Beat Earnings Estimates

by Sanghamitra Saha

These top-ranked stocks are likely to beat on the bottom lines in their next releases.

    Here's Why You Should Retain Patterson Companies (PDCO) Stock

    by Zacks Equity Research

    Patterson Companies (PDCO) continues to benefit from strength in Animal Health business and robust product portfolio. However, high debt level remains a woe.

    Idexx Laboratories (IDXX) Stock Moves -0.76%: What You Should Know

    by Zacks Equity Research

    Idexx Laboratories (IDXX) closed at $487.66 in the latest trading session, marking a -0.76% move from the prior day.

    New Study Favors Masimo's (MASI) Pulse Oximetry to Screen CCHD

    by Zacks Equity Research

    The latest study highlights the efficacy of using Masimo's (MASI) SET pulse oximetry in screening CCHD in newborns.

    Here's Why You Should Retain Glaukos (GKOS) Stock Right Now

    by Zacks Equity Research

    Glaukos (GKOS) continues to benefit from robust product portfolio and solid performing iStent technology.

      PRA Health (PRAH) Unveils Toolkit for Rare Disease Patients

      by Zacks Equity Research

      PRA Health (PRAH) launches patient-focused toolkit to lower the burden on patients with rare diseases to participate in clinical research.

        Intersect ENT (XENT) Hit by Low ENT Office Visits Amid COVID-19

        by Zacks Equity Research

        Intersect ENT (XENT) is worried about the first-quarter performance as well on the significant surge in COVID-19 case rates.

        Cooper Companies' (COO) Unit Assigns Vuzix M400 Smart Glasses

        by Zacks Equity Research

        Cooper Companies' (COO) unit assigns smart glasses to boost productivity in operations.

        Here's Why You Should Retain Change Healthcare (CHNG) Stock

        by Zacks Equity Research

        Change Healthcare (CHNG) continues to benefit from robust payment accuracy business and strategic deals. However, intense competition remains a woe.

        Here's Why You Should Hold on to ResMed (RMD) Stock for Now

        by Zacks Equity Research

        Investors continue to be optimistic about ResMed (RMD), owing to its potential in digital health and consistent high demand for its critical care products.

        Boston Scientific's (BSX) TheraSphere Approved by FDA for HCC

        by Zacks Equity Research

        Boston Scientific's (BSX) TheraSphere therapy to be made accessible to more patients following the FDA's clearance.

        IDEXX (IDXX) CAG Placement Grows Sequentially Amid COVID-19 Woes

        by Zacks Equity Research

        IDEXX's (IDXX) Global Reference Lab revenues are growing organically in the United States and in international markets.

        Zimmer Biomet (ZBH) Shows Strong Core Growth Amid Weak EMEA

        by Zacks Equity Research

        For Zimmer Biomet (ZBH), the spin-off is an important step forward to its transition into a more streamlined business with a focus on more optimized resource allocation.

        Why You Should Hold on to Illumina (ILMN) Stock for Now

        by Zacks Equity Research

        Investors continue to be optimistic about Illumina (ILMN), backed by its focus on partnerships and robust adoption of products.

        Encompass Health (EHC) Continues to Expand Presence in Texas

        by Zacks Equity Research

        Encompass Health (EHC) plans to construct a hospital in Texas for offering improved rehabilitative services, which highlights its efforts to bolster presence in the state.

        Masimo's (MASI) EMMA Favored by New Study for Children

        by Zacks Equity Research

        The latest study highlights the importance of Masimo's (MASI) EMMA for children with tracheostomy, both in home-care settings and outpatient departments.

        NuVasive (NUVA), ISSGF Expand Tie-Up With Launch of 2 Studies

        by Zacks Equity Research

        NuVasive (NUVA) extends its long-term partnership with ISSGF and initiates additional clinical studies to transform the future of spine care.

        Here's Why You Should Hold on to QIAGEN (QGEN) Stock for Now

        by Zacks Equity Research

        Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.

        Baxter (BAX) Receives FDA Nod for AK 98 Hemodialysis Machine

        by Zacks Equity Research

        Baxter (BAX) gets FDA approval for its AK 98 Hemodialysis machine that offers a compact, portable and easy-to-use system for dialysis providers.

        Here's Why You Should Retain Stryker (SYK) Stock Right Now

        by Zacks Equity Research

        Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako and broad product portfolio. However, pricing pressure raises concern.